Surgical resection with postoperative stereotactic radiosurgery versus stereotactic radiosurgery alone for large (>3 cm) multiple brain metastases: a propensity score-matched analysis
For a highly selected group of MBM patients with good performance status and a dominant mass >3 cm, resecting the largest tumor followed by SRS may be associated with improved OS and PFS compared to SRS alone.
Abstract
Purpose While surgery plus stereotactic radiosurgery (SRS) is established for solitary brain metastases, its role in multiple brain metastases (MBM) remains unclear. This study compared survival in MBM patients undergoing resection of the largest tumor plus postoperative SRS versus SRS alone. Methods This retrospective study included adults with 2–4 MBM, a dominant lesion >3 cm, and Karnofsky Performance Status ≥70. We compared patients undergoing resection of the dominant lesion plus SRS against those receiving SRS alone. Propensity-score matching (PSM) balanced baseline characteristics. Overall survival (OS), progression-free survival (PFS), and prognostic factors were analyzed. Results Of 103 patients, 16 received surgery plus SRS and 87 received SRS alone. After PSM, groups were well-balanced (median largest diameter 41.7 vs. 38.4 mm, p=0.218). Surgery plus SRS significantly improved median OS (38.9 vs. 11.6 months, p=0.013) and PFS (14.3 vs. 4.7 months, p=0.048). Multivariable regression identified surgical resection (HR 0.33, 95% CI 0.15–0.71; p=0.004), lung-cancer primary (HR 0.58, 95% CI 0.35–0.97; p=0.037), and targeted/immunotherapy (HR 0.30, 95% CI 0.18–0.51; p<0.001) as favorable prognostic factors, whereas extracranial progression predicted worse survival (HR 2.21, 95% CI 1.32–3.71; p=0.002). Conclusion For a highly selected group of MBM patients with good performance status and a dominant mass >3 cm, resecting the largest tumor followed by SRS may be associated with improved OS and PFS compared to SRS alone. Prospective studies are needed to validate these preliminary findings.
Abstract Background Real-world outcomes after stereotactic radiosurgery (SRS) for brain metastases across the full burden spectrum are limited. We tested whether overall survival (OS) in higher-burden lesion groups is non-inferior to a 5-10 lesion reference and characterized salvage patterns, including whole-brain radi...
Drew T. Bergman, M. Parker, H. Walch et al.· Neuro-Oncology Advances· 0 citations
Patients with brain metastases from CRC demonstrate higher LF after SRS compared with other primary sites, highlighting the radioresistant biology of this histology.
A. Bommireddy, Cole Billena, S. Chao et al.· Neuro-Oncology Practice· 0 citations
Combining stereotactic radiosurgery (SRS) with systemic therapy is increasingly common for brain metastases, yet real-world evidence on immunotherapy timing relative to SRS remains limited. We evaluated the association of immunotherapy and its timing with survival, intracranial control and toxicity, with exploratory an...
Mijal Ptascinsky, Antoni Skripai, Y. Hillman et al.· Journal of Neuro-Oncology· 0 citations
BACKGROUND
Postoperative stereotactic radiotherapy (SRT) is the standard adjuvant treatment after resection of brain metastases. It nevertheless requires delineation of a dynamic postsurgical cavity, delays local treatment by 3 to 6 weeks (and thus resumption of systemic therapy) and carries substantial risks of radiat...
J. Biau, F. Thillays, C. Le Fèvre et al.· Neuro-Oncology· 0 citations
Background/Aim: Hippocampal brain metastases are uncommon, and evidence regarding their management and outcomes remains limited. This study evaluated the efficacy and safety of whole-brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) for hippocampal brain metastases at a single institution. Patients and Meth...
Federico Ampil, Robert Brown, M. Norton· Anticancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.